REGENT PACIFIC (00575) announced that Deep Longevity, Inc., a global leader in explainable AI-driven aging clocks and longevity science, along with its subsidiaries (collectively referred to as Deep Longevity), will launch its expansion plan into the United States in the first quarter of 2026. This move positions Deep Longevity at the core of the world's largest and fastest-growing health market, currently valued at over $6.8 trillion. The U.S. exhibits unparalleled scale and demand for evidence-based longevity solutions.

Deep Longevity's clinically validated deep aging clocks—including BloodAge, MindAge, BiometricAge, EpigeneticAge, and the upcoming FaceAge—provide precise, multidimensional biological age assessments that go far beyond chronological age. These tools empower consumers, physicians, employers, and insurers with actionable, personalized insights to extend healthspan and delay aging.

To accelerate adoption, Deep Longevity is establishing a U.S.-based sales team, with the first two sales representatives joining on January 1, 2026. The new team will forge high-impact partnerships with longevity platforms, consumer health applications, diagnostic laboratories, wellness clinics, corporate wellness programs, insurers, employers, and premium health service providers. Initially, the team will focus on the southeastern U.S., covering Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, and West Virginia.

Deepankar Nayak, CEO of Deep Longevity, stated, "Entering the U.S. marks a pivotal milestone in Deep Longevity's journey. Our aging clocks are already trusted by world-leading clinics and platforms. With a dedicated U.S. team, we are poised to deliver personalized preventive longevity care to millions and capture a significant share of this $6.8 trillion opportunity."

Deep Longevity's technology is backed by dozens of peer-reviewed publications and multiple patented innovations. Its multimodal aging clocks integrate blood biomarkers, epigenetics, psychology, biometrics, and soon-to-be-added facial imaging to provide the most comprehensive biological aging profile available today.

Deep Longevity, Inc. (a wholly-owned subsidiary of REGENT PACIFIC) and its affiliates develop explainable AI systems that track human aging at molecular, cellular, organ, and psychological levels. The company's patented deep aging clocks offer vertical SaaS© solutions for consumers, physicians, and enterprises, delivering personalized recommendations proven to enhance health and extend healthspan.